Page last updated: 2024-11-13
elasnin
Description
elasnin: elastase inhibitor isolated from Streptomyces noboritoensis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 54685126 |
| CHEMBL ID | 54524 |
| SCHEMBL ID | 4287894 |
| MeSH ID | M0068957 |
Synonyms (17)
| Synonym |
|---|
| elasnin |
| brn 1265379 |
| 3,5-dibutyl-6-(1-butyl-2-oxoheptyl)-4-hydroxy-2h-pyran-2-one |
| 2h-pyran-2-one, 3,5-dibutyl-6-(1-butyl-2-oxoheptyl)-4-hydroxy- |
| CHEMBL54524 , |
| 68112-21-0 |
| 3,5-dibutyl-2-hydroxy-6-(6-oxoundecan-5-yl)-4h-pyran-4-one |
| bdbm50405203 |
| 5-18-03-00063 (beilstein handbook reference) |
| SCHEMBL4287894 |
| 3,5-dibutyl-4-hydroxy-6-(6-oxoundecan-5-yl)-2h-pyran-2-one |
| HB3885 |
| DTXSID00987589 |
| 3,5-dibutyl-4-hydroxy-6-(6-oxoundecan-5-yl)pyran-2-one |
| CS-0086907 |
| HY-124556 |
| AKOS040748312 |
Research Excerpts
Overview
Elasnin is a recently reported antibiofilm agent that is effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) Elasnin exhibits high efficiency in inhibiting marine biofilms and biofouling.
| Excerpt | Reference | Relevance |
|---|
| "Elasnin is a recently reported antibiofilm agent that is effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). " | ( Elasnin Effectively Eradicates Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus Biofilms.
Lam, H; Long, L; Qian, PY; Sulaiman, JE, 2022) | 3.61 |
| "Elasnin is a potent antibiofilm compound that exhibits high efficiency in inhibiting marine biofilms and biofouling, but its mode of action remains unclear." | ( Mechanistic Insight into the Inhibitory Activity of Elasnin-Based Coating against Early Marine Biofilms.
Chen, F; Huang, Y; Lam, H; Long, L; Luo, F; Qian, PY; Sulaiman, JE; Tang, JW; Wong, W; Wu, C; Wu, L; Xiao, Y, 2023) | 1.88 |
Protein Targets (3)
Inhibition Measurements
Biological Processes (25)
Molecular Functions (8)
Ceullar Components (12)
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID66470 | Inhibitory activity against human leukocyte elastase (HL elastase) expressed as inhibitory constant | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
| Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones. |
| AID52466 | Inhibitory activity against bovine Chymotrypsinogen expressed as inhibitory constant | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
| Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones. |
| AID156214 | Inhibitory activity against porcine pancreatic elastase (PP elastase) expressed as inhibitory constant | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
| Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones. |
| AID19471 | Partition coefficient (logP) (octanol/saline) | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
| Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.00
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 20.00 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.45 (4.65) | | Search Engine Demand Index | 15.26 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |